Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. 2022

Katsunori Matsushita, and Shogo Kobayashi, and Hirofumi Akita, and Masamitsu Konno, and Ayumu Asai, and Takehiro Noda, and Yoshifumi Iwagami, and Tadafumi Asaoka, and Kunihito Gotoh, and Masaki Mori, and Yuichiro Doki, and Hidetoshi Eguchi, and Hideshi Ishii
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Pancreatic ductal adenocarcinoma is one of the most aggressive malignancies, and often involves invasion and distant metastasis from the early tumor stages. Myosin II reportedly plays a key role in regulating tumor progression and metastasis. We examined whether myosin regulatory light polypeptide 9 (MYL9) regulates cancer cell proliferation. To investigate the expression pattern and clinical significance of MYL9 in pancreatic ductal adenocarcinoma, we performed immunohistochemical analysis of samples collected from 101 patients with pancreatic ductal adenocarcinoma. The expression of MYL9 was investigated to evaluate its functional role and contribution to proliferation and apoptosis in pancreatic ductal adenocarcinoma cells in vitro. The results showed that MYL9 was predominantly expressed in the cytoplasm and membrane of pancreatic ductal adenocarcinoma cells. Multivariate analysis indicated that MYL9 acted as an independent prognostic factor for overall survival and distant metastasis-free survival. MYL9 expression was strongly associated with malignancy in in vitro analyses, including proliferation and anti-apoptotic activities. Our findings suggest that MYL9 is an independent prognostic factor of pancreatic ductal adenocarcinoma. MYL9 is a crucial biomarker and potential therapeutic target for pancreatic ductal adenocarcinoma.

UI MeSH Term Description Entries
D009218 Myosins A diverse superfamily of proteins that function as translocating proteins. They share the common characteristics of being able to bind ACTINS and hydrolyze MgATP. Myosins generally consist of heavy chains which are involved in locomotion, and light chains which are involved in regulation. Within the structure of myosin heavy chain are three domains: the head, the neck and the tail. The head region of the heavy chain contains the actin binding domain and MgATPase domain which provides energy for locomotion. The neck region is involved in binding the light-chains. The tail region provides the anchoring point that maintains the position of the heavy chain. The superfamily of myosins is organized into structural classes based upon the type and arrangement of the subunits they contain. Myosin ATPase,ATPase, Actin-Activated,ATPase, Actomyosin,ATPase, Myosin,Actin-Activated ATPase,Actomyosin ATPase,Actomyosin Adenosinetriphosphatase,Adenosine Triphosphatase, Myosin,Adenosinetriphosphatase, Actomyosin,Adenosinetriphosphatase, Myosin,Myosin,Myosin Adenosinetriphosphatase,ATPase, Actin Activated,Actin Activated ATPase,Myosin Adenosine Triphosphatase
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D018994 Myosin Light Chains The smaller subunits of MYOSINS that bind near the head groups of MYOSIN HEAVY CHAINS. The myosin light chains have a molecular weight of about 20 KDa and there are usually one essential and one regulatory pair of light chains associated with each heavy chain. Many myosin light chains that bind calcium are considered "calmodulin-like" proteins. Myosin Alkali Light Chains,Myosin Alkali Light Chain,Myosin Essential Light Chain,Myosin Essential Light Chains,Myosin Light Chain,Myosin Regulatory Light Chain,Myosin Regulatory Light Chains,Light Chain, Myosin,Light Chains, Myosin
D021441 Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS. Pancreatic Ductal Carcinoma,Carcinoma, Ductal, Pancreatic,Duct-Cell Carcinoma of the Pancreas,Duct-Cell Carcinoma, Pancreas,Ductal Carcinoma of the Pancreas,Pancreatic Duct Cell Carcinoma,Carcinoma, Pancreas Duct-Cell,Carcinomas, Pancreas Duct-Cell,Carcinomas, Pancreatic Ductal,Duct Cell Carcinoma of the Pancreas,Duct Cell Carcinoma, Pancreas,Duct-Cell Carcinomas, Pancreas,Ductal Carcinoma, Pancreatic,Ductal Carcinomas, Pancreatic,Pancreas Duct-Cell Carcinoma,Pancreas Duct-Cell Carcinomas,Pancreatic Ductal Carcinomas

Related Publications

Katsunori Matsushita, and Shogo Kobayashi, and Hirofumi Akita, and Masamitsu Konno, and Ayumu Asai, and Takehiro Noda, and Yoshifumi Iwagami, and Tadafumi Asaoka, and Kunihito Gotoh, and Masaki Mori, and Yuichiro Doki, and Hidetoshi Eguchi, and Hideshi Ishii
March 2019, Zhonghua wai ke za zhi [Chinese journal of surgery],
Katsunori Matsushita, and Shogo Kobayashi, and Hirofumi Akita, and Masamitsu Konno, and Ayumu Asai, and Takehiro Noda, and Yoshifumi Iwagami, and Tadafumi Asaoka, and Kunihito Gotoh, and Masaki Mori, and Yuichiro Doki, and Hidetoshi Eguchi, and Hideshi Ishii
July 2017, Journal of clinical pathology,
Katsunori Matsushita, and Shogo Kobayashi, and Hirofumi Akita, and Masamitsu Konno, and Ayumu Asai, and Takehiro Noda, and Yoshifumi Iwagami, and Tadafumi Asaoka, and Kunihito Gotoh, and Masaki Mori, and Yuichiro Doki, and Hidetoshi Eguchi, and Hideshi Ishii
October 2013, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Katsunori Matsushita, and Shogo Kobayashi, and Hirofumi Akita, and Masamitsu Konno, and Ayumu Asai, and Takehiro Noda, and Yoshifumi Iwagami, and Tadafumi Asaoka, and Kunihito Gotoh, and Masaki Mori, and Yuichiro Doki, and Hidetoshi Eguchi, and Hideshi Ishii
April 2019, Human pathology,
Katsunori Matsushita, and Shogo Kobayashi, and Hirofumi Akita, and Masamitsu Konno, and Ayumu Asai, and Takehiro Noda, and Yoshifumi Iwagami, and Tadafumi Asaoka, and Kunihito Gotoh, and Masaki Mori, and Yuichiro Doki, and Hidetoshi Eguchi, and Hideshi Ishii
January 2012, Asian Pacific journal of cancer prevention : APJCP,
Katsunori Matsushita, and Shogo Kobayashi, and Hirofumi Akita, and Masamitsu Konno, and Ayumu Asai, and Takehiro Noda, and Yoshifumi Iwagami, and Tadafumi Asaoka, and Kunihito Gotoh, and Masaki Mori, and Yuichiro Doki, and Hidetoshi Eguchi, and Hideshi Ishii
March 2015, Diagnostic pathology,
Katsunori Matsushita, and Shogo Kobayashi, and Hirofumi Akita, and Masamitsu Konno, and Ayumu Asai, and Takehiro Noda, and Yoshifumi Iwagami, and Tadafumi Asaoka, and Kunihito Gotoh, and Masaki Mori, and Yuichiro Doki, and Hidetoshi Eguchi, and Hideshi Ishii
April 2004, Clinical cancer research : an official journal of the American Association for Cancer Research,
Katsunori Matsushita, and Shogo Kobayashi, and Hirofumi Akita, and Masamitsu Konno, and Ayumu Asai, and Takehiro Noda, and Yoshifumi Iwagami, and Tadafumi Asaoka, and Kunihito Gotoh, and Masaki Mori, and Yuichiro Doki, and Hidetoshi Eguchi, and Hideshi Ishii
August 2002, Clinical cancer research : an official journal of the American Association for Cancer Research,
Katsunori Matsushita, and Shogo Kobayashi, and Hirofumi Akita, and Masamitsu Konno, and Ayumu Asai, and Takehiro Noda, and Yoshifumi Iwagami, and Tadafumi Asaoka, and Kunihito Gotoh, and Masaki Mori, and Yuichiro Doki, and Hidetoshi Eguchi, and Hideshi Ishii
October 2015, Genetics and molecular research : GMR,
Katsunori Matsushita, and Shogo Kobayashi, and Hirofumi Akita, and Masamitsu Konno, and Ayumu Asai, and Takehiro Noda, and Yoshifumi Iwagami, and Tadafumi Asaoka, and Kunihito Gotoh, and Masaki Mori, and Yuichiro Doki, and Hidetoshi Eguchi, and Hideshi Ishii
January 2004, Oncogene,
Copied contents to your clipboard!